CClinicalTrials.gg
TerminatedNCT02542241CELTAUpdated Jun 11, 2020

Hypertonic Saline Resuscitation in Trauma Patients After Hemorrhage Control

A Phase 4 interventional study of Sodium Chloride [3%] and Sodium Chloride [0.9%] in Abdominal Injuries, sponsored by Fundacion Clinica Valle del Lili. Terminated at 1 site in Colombia. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2020-06-11.

Sponsored by Fundacion Clinica Valle del Lili · Phase 4, Interventional, and Treatment

Why this study was terminated
lack of funds to continue recruitment
Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

This study aimed to determine whether hypertonic saline solution is effective in the resuscitation of injured patients undergoing abdominal damage control surgery regarding early closure of the abdominal wall.

Read the detailed description

A double-blind, controlled, randomized clinical trial was conducted to determine the impact of an infusion of hypertonic saline 3% vs. isotonic saline 0.9% at a dose of 50 mL/hr for the first 72 hours in patients with abdominal trauma requiring damage control surgery regarding some clinically relevant outcomes. These outcomes were: The timing of abdominal cavity closure, fluids balance, abdominal hypertension, and abdominal compartment syndrome occurrence, organ dysfunction, and 28 days' mortality.

02

Conditions studied

  • Abdominal Injuries

Browse trials for

Keywords

  • Open abdomen
  • hypertonic saline solution
  • intensive care
03

In context

Abdominal Injuries

70 studies on the registry are indexed under Abdominal Injuries; 18 are open to participants now.

This study's enrollment of 52 is below the median of 104 across 34 interventional studies indexed under Abdominal Injuries.

Browse Abdominal Injuries studies →

Lead sponsor

Fundacion Clinica Valle del Lili is the lead sponsor of 23 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Abdominal trauma requiring damage control surgery.
  • Acceptance by the patient or by a proxy to be included in the trial.

Exclusion criteria

Exclusion Criteria:

  • Concomitant severe head trauma, defined by a Glasgow score \<9, before receiving sedation or by the presence of cerebral edema or intracranial injury on a CT-scan.
  • Pregnancy
  • Patient not included 4 hours or more after damage control surgery.
  • Damage control laparotomy performed for other indications other than trauma.
  • Not index damage control laparotomy
  • No acceptance to participate in the study.
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Sodium Chloride [3%]

    Drug: Sodium Chloride [3%]

  • Active comparator
    Sodium Chloride [0.9%]

    Drug: Sodium Chloride [0.9%]

Interventions

  • DrugSodium Chloride [3%]

    Patients in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).

    Also known as: Hypertonic Saline Solution, NaCl

  • DrugSodium Chloride [0.9%]

    Patients in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc/hour rate, which will be administered by an infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).

    Also known as: Physiologic Saline Solution, Normal Saline

06

What researchers measure

Primary outcomes

  1. Abdominal wall closure

    Proportion of patients in which closure of abdominal wall was achieved in the first 7 days after injury.

    Time frame: 7 days

Secondary outcomes

  1. Fluid Balance measured in cm3

    Fluid balance during the first 72 hours after injury. Defined as the difference between the amount of fluids taken into the body and the amount excreted or lost. Input includes oral fluids, infused intravenous fluids and blood products. Output includes fluid loss as urine, emesis and wound drainage among others.

    Time frame: 72 hours

  2. Incidence of Abdominal compartment syndrome

    Incidence of abdominal compartment syndrome (defined as sustained intra-abdominal pressure \> 20 mmHg, accompanied by new organ dysfunction, defined as a score \> 2, under the SOFA scale compromising lung, kidney, or heart) during the first 7 days after injury.

    Time frame: 7 days

  3. Incidence of Organ Failure

    Incidence of organ failure (defined as SOFA score greater than 2).

    Time frame: 7 days

  4. Mortality

    28 day mortality rate

    Time frame: 28 days

07

Study locations

1 site
  • Fundacion Clinica Valle del Lili
    Cali, Valle Del Cauca, Colombia
08

References and documents

Individual participant data

Plan to share: No — The individual participant data contained in the datasets generated and/or analyzed for the current study are not publicly available as recommended by the local ethical and research committee involving human beings (Fundación Valle del Lili, Cali, Colombia) but could be available from the corresponding author on reasonable request and under prior approval by such committee.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02542241
Lead sponsor
Fundacion Clinica Valle del Lili
Responsible party
Alberto Federico García (MD., Fundacion Clinica Valle del Lili) — Principal investigator
First posted
Sep 4, 2015
Start date
Nov 27, 2015
Primary completion
Sep 4, 2018
Completion
Sep 4, 2018
Last update
Jun 11, 2020

Study contacts

Alberto F García, MD
principal investigator · Fundacion Clinica Valle del Lili

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion